Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence.

Nicholas J. Robert,Joyce OShaughnessy,Srinivas Annavarapu,Jie Zhou,Jesse A. Sussell,Anna Cheng,Anita Fung

Risk of recurrence in patients with HER2+ breast cancer who achieved a pathological complete response (pCR) after neoadjuvant pertuzumab and trastuzumab (nPT), and received adjuvant trastuzumab (aT): Real-world evidence.

2020

Nicholas J. Robert
Joyce OShaughnessy
Srinivas Annavarapu
Jie Zhou
Jesse A. Sussell
Anna Cheng
Anita Fung

e12648Background: The real-world risk of disease recurrence in patients with HER2+ early breast cancer who achieved pCR after receipt of nPT-based regimens and aT is unclear. Methods: Women with HE...

Keywords:

Trastuzumab
Pertuzumab
Adjuvant
Oncology
Internal medicine
real world evidence
Breast cancer
Pathological
Pathology
in patient
complete response
Medicine
Disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations